GSK abandons $3bn-plus plan to sell older drugs portfolio

Pharmaceutical giant GlaxoSmithKline has decided not to sell a portfolio of older drugs marketed in North America and Europe, despite strong interest from private equity firms and offers upwards of $3bn.